Novel Agents for Chronic Lymphocytic Leukemia to Address Resistance
Published in Cancer and Genetics & Genomics
BTK Degraders
- Mechanism: These agents degrade Bruton tyrosine kinase (BTK), a key protein in B-cell receptor signaling, which is essential for CLL cell survival.
- Examples: NX-2127, BGB-16673, and NX-5948 have shown efficacy in relapsed/refractory (R/R) CLL.
- Non-Covalent BTK Inhibitors
- Mechanism: These reversible inhibitors target BTK without relying on covalent binding, overcoming resistance caused by mutations like C481S.
- Examples:
- Pirtobrutinib: Demonstrates high selectivity and efficacy, even in heavily pretreated patients.
- Nemtabrutinib: Similar efficacy but less well-tolerated compared to pirtobrutinib.
- BH3 Mimetics
- Mechanism: Mimic pro-apoptotic proteins to inhibit anti-apoptotic BCL2 family proteins, promoting cell death.
- Examples: Venetoclax targets BCL2, while newer agents like sonrotoclax aim to overcome resistance caused by mutations like Gly101Val.
- Monoclonal Antibodies
- Mechanism: Target antigens on CLL cells (e.g., CD20, CD19, CD37) to induce apoptosis or recruit immune cells for cytotoxicity.
- Examples:
- Obinutuzumab: Anti-CD20 antibody with improved efficacy over rituximab.
- Otlertuzumab: Anti-CD37 antibody triggering apoptosis and antibody-dependent cell-mediated cytotoxicity.
- Bispecific Antibodies
- Mechanism: Bind both CLL cell antigens (e.g., CD19, CD20, BCMA) and CD3 on T cells, redirecting T cells to kill leukemia cells.
- Examples:
- Blinatumomab: Targets CD19 and CD3.
- Teclistamab: Targets BCMA and CD3.
- Chimeric Antigen Receptor (CAR) T Cell Therapies
- Mechanism: Genetically modified T cells express CARs targeting antigens like CD19, enabling direct killing of CLL cells.
- Examples: Lisocabtagene maraleucel (CD19 CAR T therapy).
- Siglec-6 Monoclonal Antibodies
- Mechanism: Target Siglec-6, a novel antigen absent on healthy cells, to activate T cells and eliminate CLL cells.
- Examples: RC-1 and RC-2 antibodies engineered for high specificity and potency.
- ROR1-Directed Therapies
- Mechanism: Target ROR1, a receptor tyrosine kinase expressed selectively on CLL cells.
- Examples: Cirmtuzumab and zilovertamab vedotin.
- Vg9Vd2-T Cell Engagers
- Mechanism: Activate Vg9Vd2-T cells to lyse CLL cells by targeting CD1d, a molecule expressed on leukemic cells.
- Example: Bispecific single-domain antibodies designed to boost T cell responses.
- Anti-BAFF Antibodies
- Mechanism: Target BAFF, a factor promoting CLL cell survival, to induce apoptosis.
- Examples: Belimumab and ianalumab.
- Precision Medicine Approaches
- Mechanism: Use predictive biomarkers (e.g., TP53, IGHV mutations) and machine learning algorithms to tailor treatments based on tumor heterogeneity and resistance profiles.
These novel agents address unmet clinical needs by targeting specific pathways, overcoming resistance mechanisms, and enhancing immune responses, offering hope for improved outcomes in CLL treatment.
Follow the Topic
-
Discover Oncology
This is a fully open access general oncology journal that aims to provide a unified forum for researchers and clinicians. The journal spans from basic and translational science, to preclinical, clinical, and epidemiology, and welcomes content that interfaces at all levels of cancer research.
Related Collections
With Collections, you can get published faster and increase your visibility.
Prostate Cancer - Advances in Diagnosis and Treatment
Prostate cancer remains one of the most prevalent malignancies among men globally, accounting for a significant proportion of cancer-related morbidity and mortality. With increasing life expectancy and improved diagnostic techniques, the incidence and detection rates of prostate cancer continue to rise, highlighting the critical need for advances in both diagnostic and therapeutic approaches. Recent breakthroughs in molecular biology, imaging technologies, and genetic profiling have significantly enhanced early detection and prognostic accuracy, allowing for more personalized patient care.
This Collection aims to present comprehensive insights into recent developments and cutting-edge research in prostate cancer diagnosis and treatment. Key topics include novel biomarkers for early detection, advances in imaging modalities such as multiparametric MRI and PET-PSMA, genomic and epigenetic factors influencing disease progression, and emerging therapeutic strategies including robotic-assisted surgery, radiotherapy advancements, immunotherapy, and precision medicine approaches. Additionally, the collection will explore mechanisms of resistance to therapy, the role of tumor microenvironment in disease evolution, and strategies to overcome treatment barriers. We invite contributions focusing on translational and clinical research, innovative diagnostic methods, therapeutic innovations, and studies that bridge fundamental discoveries with clinical application to improve patient outcomes in prostate cancer.
Keywords: prostate cancer, biomarkers, imaging, genomics, precision medicine, robotic surgery, radiotherapy, immunotherapy, tumor microenvironment
Publishing Model: Open Access
Deadline: Jan 04, 2027
The Evolving Landscape of Lung Cancer: Advances in Diagnosis, Treatment Strategies, and Simultaneous Care
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, although recent years have seen remarkable progress in its clinical management. This Collection aims to deepen the evolving landscape of lung cancer through a comprehensive lens, including early diagnosis, molecular profiling (through liquid and tissue), therapeutic innovation, and simultaneous care strategies. The Collection will gather original research, reviews, short reports or letters and case studies focused on:
advances in early detection and biomarker discovery and development;
the evolution of precision oncology and molecular profiling;
updates on systemic therapies, including immunotherapy and targeted agents;
novel treatment combination strategies,
the increasing integration of simultaneous care into multidisciplinary models for improving patient outcomes.
Keywords: lung cancer; precision oncology; immunotherapy; molecular diagnostics; simultaneous care
Publishing Model: Open Access
Deadline: Dec 04, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in
Part of a collection:
The Convergence of Targeted Precision Medicine: Future of Oncology Therapeutics